A method for evaluation of proton plan robustness towards inter-fractional motion applied to pelvic lymph node irradiation

References

• Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005;104:1129–37.
   PubMed Web of Science ®Google Scholar
• Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: An overview. Eur J Cancer 2010;46: 3040–52.
   PubMed Web of Science ®Google Scholar
• Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, et al. Management of prostate cancer patients with lymph node involvement: A rapidly evolving paradigm. Cancer Treat Rev 2012;38:956–67.
   PubMed Web of Science ®Google Scholar
• Heemsbergen WD, Al-Mamgani A, Slot A, Dielwart MFH, Lebesque JV. Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiother Oncol 2014;110:104–9.
   PubMed Web of Science ®Google Scholar
• Kok D, Gill S, Bressel M, Byrne K, Kron T, Fox C, et al. Late toxicity and biochemical control in 554 prostate cancer patients treated with and without dose escalated image guided radiotherapy. Radiother Oncol 2013;107:140–6.
   PubMed Web of Science ®Google Scholar
• Fonteyne V, Lumen N, Ost P, Van Praet C, Vandecasteele K, De Gersem Ir W, et al. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: Early late toxicity and 3-year clinical outcome. Radiother Oncol 2013;109:229–34.
   PubMed Web of Science ®Google Scholar
• McDonald AM, Jacob R, Dobelbower MC, Kim RY, Fiveash JB. Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer. Acta Oncol 2013; 52:1181–8.
   PubMed Web of Science ®Google Scholar
• Vargas C, Wagner M, Mahajan C, Indelicato D, Fryer A, Falchook A, et al. Proton therapy coverage for prostate cancer treatment. Int J Radiat Oncol Biol Phys 2008;70: 1492–501.
   PubMed Web of Science ®Google Scholar
• Widesott L, Pierelli A, Fiorino C, Lomax AJ, Amichetti M, Cozzarini C, et al. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: Dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis. Int J Radiat Oncol Biol Phys 2011;80:1589–600.
   PubMed Web of Science ®Google Scholar
• Thörnqvist S, Muren LP, Bentzen L, Hysing LB, Høyer M, Grau C, et al. Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets. Acta Oncol 2013;52:521–7.
   PubMed Web of Science ®Google Scholar
• Thörnqvist S, Bentzen L, Petersen JBB, Hysing LB, Muren LP. Plan robustness of simultaneous integrated boost radiotherapy of prostate and lymph nodes for different image-guidance and delivery techniques. Acta Oncol 2011; 50:926–34.
   PubMed Web of Science ®Google Scholar
• Fellin F, Azzeroni R, Maggio A, Lorentini S, Cozzarini C, Di Muzio N, et al. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: A treament planning comparison. Radiother Oncol 2013;107:207–12.
   PubMed Web of Science ®Google Scholar
• Chera BS, Vargas C, Morris CG, Louis D, Flampouri S, Yeung D, et al. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009;75:994–1002.
   PubMed Web of Science ®Google Scholar
• Henderson RH, Hoppe BS, Marcus RB, Mendenhall WM, Nichols RC, Li Z, et al. Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: Results of two prospective trials. Acta Oncol 2013;52:463–9.
   PubMed Web of Science ®Google Scholar
• Thor M, Apte A, Deasy JO, Muren LP. Statistical simulations to estimate motion-inclusive dose-volume histograms for prediction of rectal morbidity following radiotherapy. Acta Oncol 2013;52:666–75.
   PubMed Web of Science ®Google Scholar
• Thörnqvist S, Hysing LB, Zolnay AG, Söhn M, Hoogeman MS, Muren LP, et al. Treatment simulations with a statistical deformable motion model to evaluate margins for multiple targets in radiotherapy for high-risk prostate cancer. Radiother Oncol 2013;109:344–9.
   PubMed Web of Science ®Google Scholar
• Vees H, Dipasquale G, Nouet P, Zilli T, Cozzi L, Miralbell R. Pelvic lymph node irradiation including pararectal sentinel nodes for prostate cancer patients: Treatment optimization comparing intensity modulated x-rays, volumetric modulated arc therapy, and intensity modulated proton therapy. Technol Cancer Res Treat 2015;14:181–9.
   PubMed Web of Science ®Google Scholar
• Trofimov A, Nguyen PL, Efstathiou JA, Wang Y, Lu H-M, Engelsman M, et al. Interfractional variations in the setup of pelvic bony anatomy and soft tissue, and their implications on the delivery of proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2011;80:928–37.
   PubMed Web of Science ®Google Scholar
• Lu H-M. A potential method for in vivo range verification in proton therapy treatment. Phys Med Biol 2008;53:1413–24.
   PubMed Web of Science ®Google Scholar
• Fredriksson A, Forsgren A, Hårdemark B. Minimax optimization for handling range and setup uncertainties in proton therapy. Med Phys 2011;38:1672–84.
   PubMed Web of Science ®Google Scholar
• Unkelbach J, Chan TCY, Bortfeld T. Accounting for range uncertainties in the optimization of intensity modulated proton therapy. Phys Med Biol 2007;52:2755–73.
   PubMed Web of Science ®Google Scholar
• Unkelbach J, Bortfeld T, Martin BC, Soukup M. Reducing the sensitivity of IMPT treatment plans to setup errors and range uncertainties via probabilistic treatment planning. Med Phys 2009;36:149–63.
   PubMed Web of Science ®Google Scholar
• Muren LP, Wasbø E, Helle SI, Hysing LB, Karlsdottir A, Odland OH, et al. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: Planning procedures and early experiences. Int J Radiat Oncol Biol Phys 2008;71:1034–41.
   PubMed Web of Science ®Google Scholar
• Thörnqvist S, Petersen JBB, Høyer M, Bentzen LN, Muren LP. Propagation of target and organ at risk contours in radiotherapy of prostate cancer using deformable image registration. Acta Oncol 2010;49:1023–32.
   PubMed Web of Science ®Google Scholar
• Casares-Magaz O, Toftegaard J, Muren LP, Kallehauge JF, Bassler N, Poulsen PR, et al. A method for selection of beam angles robust to intra-fractional motion in proton therapy of lung cancer. Acta Oncol 2014;53:1058–63.
   PubMed Web of Science ®Google Scholar
• Krämer M, Jäkel O, Haberer T, Rietzel E, Schardt D, Scholz M, et al. Treatment planning for scanned ion beams. Radiother Oncol 2004;73(Suppl 2):S80–5.
   PubMed Web of Science ®Google Scholar
• Adamczyk M, Piotrowski T, Adamiak E, Malicki J. Dosimetric consequences of prostate-based couch shifts on the precision of dose delivery during simultaneous IMRT irradiation of the prostate, seminal vesicles and pelvic lymph nodes. Phys Med 2014;30:228–33.
   PubMed Web of Science ®Google Scholar
• Toftegaard J, Petersen JBB, Bassler N. PyTRiP – a toolbox and GUI for the proton/ion therapy planning system TRiP. J Phys Conf Ser 2014;489:012045.
   Google Scholar
• Chaikh A, Giraud J-Y, Perrin E, Bresciani J-P, Balosso J. The choice of statistical methods for comparisons of dosimetric data in radiotherapy. Radiat Oncol 2014;9:205.
   PubMed Web of Science ®Google Scholar
• Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: A treatment planning comparison. Int J Radiat Oncol Biol Phys 2007;69:444–53.
   PubMed Web of Science ®Google Scholar
• Cuaron JJ, Harris AA, Chon B, Tsai H, Larson G, Hartsell WF, et al. Anterior-oriented proton beams for prostate cancer: A multi-institutional experience. Acta Oncol 2015;54:868–74.
   PubMed Web of Science ®Google Scholar
• Meijer GJ, de Klerk J, Bzdusek K, van den Berg HA, Janssen R, Kaus MR, et al. What CTV-to-PTV margins should be applied for prostate irradiation? Four-dimensional quantitative assessment using model-based deformable image registration techniques. Int J Radiat Oncol Biol Phys 2008;72:1416–25.
   PubMed Web of Science ®Google Scholar
• Engelsman M, Schwarz M, Dong L. Physics controversies in proton therapy. Semin Radiat Oncol 2013;23:88–96.
   PubMed Web of Science ®Google Scholar
• Cheung JP, Park PC, Court LE, Ronald Zhu X, Kudchadker RJ, Frank SJ, et al. A novel dose-based positioning method for CT image-guided proton therapy. Med Phys 2013;40: 051714.
   Web of Science ®Google Scholar
• Park PC, Cheung JP, Zhu XR, Lee AK, Sahoo N, Tucker SL, et al. Statistical assessment of proton treatment plans under setup and range uncertainties. Int J Radiat Oncol Biol Phys 2013;86:1007–13.
   PubMed Web of Science ®Google Scholar